Copied from IHUB,
Fletch
falconer66a Saturday, 05/18/19 01:54:25 PM
Re: Boopka post# 193315
Post # of 193336
Anavex In Five Years
The diversity, amplitude, and application of Anavex treatments against what appears to be a multitude of human diseases and conditions remains to be fully discovered. In consideration of the now expansive body of knowledge about the Anavex sigma-1 receptor agonists, two important perspectives appear.
First, the Anavex molecules are unique; not to be compared to any other class of pharmaceuticals. They function, have multiple cellular mechanisms of action, like no others. A few other molecules may mimic certain portions of Anavex sigma-1 receptor agonist functionalities, but altogether, nothing compares. Simply, they both facilitate and restore a diversity of normalized cell functions or reaction sequences, both on a molecular and organelle level.
Presently, profound efficacies against at least three central nervous system conditions, Rett syndrome, Parkinson’s dementia, and Alzheimer’s disease are about to be adequately substantiated. But a multitude of murine studies reveal a far greater diversity of target diseases and conditions, yet to be tested by Anavex testing in humans. With clinical affirmation of Anavex therapy against just the three current CNS diseases, clinical neurology in particular, and 21st-century medicine in general, will be transformed.
Well and good. That’s what those of us who follow, study, and understand the Anavex science believe will be the case. All of that will be but an early chapter in the Anavex story. The far greater story will be the science and clinical outcomes to be told in new chapters, to be written soon enough. By then, Parkinson’s and Alzheimer’s will have a new standard of care, Anavex 2-73, successfully treated at the earliest, even pre-symptomatic diagnosis.
After that, there will be no stopping of the Anavex machine. Here’s the second, far more important consideration. Murine evidence supports the notion that Anavex sigma-1 receptor agonists will have a multitude of successful therapeutic applications; not just for a few CNS diseases. The Anavex pipeline listing reveals but a few of these. Doubtless, Anavex has commissioned murine tests of all of their molecules (particularly, Anavex 3-71) against a multitude of diseases and conditions. So far, they’ve kept the results of those to themselves. But I have no doubt that what they’ve discovered, perhaps with appropriate adjunct therapies where Anavex molecules enhance conventional therapies, is profoundly significant — things that will change the practice of medicine more than anything in the past. Restoration or support of normalized cell chemistry. With that, normalized systemic health happens.
Anavex insiders know the details of all of this. They keep all of it as protected trade secrets. Then when appropriate, they will file international patents. Then, with the ample revenues from Anavex 2-73 treating CNS diseases, they will conduct new human clinical trials for the many other diseases Anavex sigma-1 receptor agonists will treat. Anavex 3-71 will be the lead horse in that charge.
Ok, that’s all just hopeful but hazy conjecture, right? In the past, dozens of new drugs have evoked similar visions of medical grandeur and transformation. Anavex will be no different.
Yes, no different if the three clinical trials fail; or if no other diseases or conditions are found to be open to Anavex therapy. But as a biologist who to a useful degree understands a bit of the arcane biochemistry and cytology of the Anavex molecules in dysfunctional cells, neurons in particular, the following is the most encouraging.
It’s simply this. In therapeutic concentrations, the Anavex molecules are not toxic. They don’t inadvertently disrupt or complicate other cellular chemistries; or don’t disfigure or disable functioning enzymes, hormones, or other essential molecules or ions. Presently, not a shred of evidence that Anavex sigma-1 receptor agonists act in the cell as highly active, exogenous (foreign) reactants. Conversely, they enter, reside, and function (chemically react) in the cell most innocuously. They function in the manner of a nutrient, not an exogenous, synthetic drug. No untoward side reactions. No disruptions of normal cell functions. Unique. No other molecules or drugs like them. In the coming years, new, ever larger chapters in the Anavex story book will be written. Not fiction. Something like an iceberg drifting ever more southward into the warm Atlantic.
Wait a minute? Didn’t someone mention an Anavex iceberg sometime ago? What, per chance, might have prompted such an utterance? All of the above.
https://investorshub.advfn.com/boards/read_ms...=148898022
Fletch
falconer66a Saturday, 05/18/19 01:54:25 PM
Re: Boopka post# 193315
Post # of 193336
Anavex In Five Years
The diversity, amplitude, and application of Anavex treatments against what appears to be a multitude of human diseases and conditions remains to be fully discovered. In consideration of the now expansive body of knowledge about the Anavex sigma-1 receptor agonists, two important perspectives appear.
First, the Anavex molecules are unique; not to be compared to any other class of pharmaceuticals. They function, have multiple cellular mechanisms of action, like no others. A few other molecules may mimic certain portions of Anavex sigma-1 receptor agonist functionalities, but altogether, nothing compares. Simply, they both facilitate and restore a diversity of normalized cell functions or reaction sequences, both on a molecular and organelle level.
Presently, profound efficacies against at least three central nervous system conditions, Rett syndrome, Parkinson’s dementia, and Alzheimer’s disease are about to be adequately substantiated. But a multitude of murine studies reveal a far greater diversity of target diseases and conditions, yet to be tested by Anavex testing in humans. With clinical affirmation of Anavex therapy against just the three current CNS diseases, clinical neurology in particular, and 21st-century medicine in general, will be transformed.
Well and good. That’s what those of us who follow, study, and understand the Anavex science believe will be the case. All of that will be but an early chapter in the Anavex story. The far greater story will be the science and clinical outcomes to be told in new chapters, to be written soon enough. By then, Parkinson’s and Alzheimer’s will have a new standard of care, Anavex 2-73, successfully treated at the earliest, even pre-symptomatic diagnosis.
After that, there will be no stopping of the Anavex machine. Here’s the second, far more important consideration. Murine evidence supports the notion that Anavex sigma-1 receptor agonists will have a multitude of successful therapeutic applications; not just for a few CNS diseases. The Anavex pipeline listing reveals but a few of these. Doubtless, Anavex has commissioned murine tests of all of their molecules (particularly, Anavex 3-71) against a multitude of diseases and conditions. So far, they’ve kept the results of those to themselves. But I have no doubt that what they’ve discovered, perhaps with appropriate adjunct therapies where Anavex molecules enhance conventional therapies, is profoundly significant — things that will change the practice of medicine more than anything in the past. Restoration or support of normalized cell chemistry. With that, normalized systemic health happens.
Anavex insiders know the details of all of this. They keep all of it as protected trade secrets. Then when appropriate, they will file international patents. Then, with the ample revenues from Anavex 2-73 treating CNS diseases, they will conduct new human clinical trials for the many other diseases Anavex sigma-1 receptor agonists will treat. Anavex 3-71 will be the lead horse in that charge.
Ok, that’s all just hopeful but hazy conjecture, right? In the past, dozens of new drugs have evoked similar visions of medical grandeur and transformation. Anavex will be no different.
Yes, no different if the three clinical trials fail; or if no other diseases or conditions are found to be open to Anavex therapy. But as a biologist who to a useful degree understands a bit of the arcane biochemistry and cytology of the Anavex molecules in dysfunctional cells, neurons in particular, the following is the most encouraging.
It’s simply this. In therapeutic concentrations, the Anavex molecules are not toxic. They don’t inadvertently disrupt or complicate other cellular chemistries; or don’t disfigure or disable functioning enzymes, hormones, or other essential molecules or ions. Presently, not a shred of evidence that Anavex sigma-1 receptor agonists act in the cell as highly active, exogenous (foreign) reactants. Conversely, they enter, reside, and function (chemically react) in the cell most innocuously. They function in the manner of a nutrient, not an exogenous, synthetic drug. No untoward side reactions. No disruptions of normal cell functions. Unique. No other molecules or drugs like them. In the coming years, new, ever larger chapters in the Anavex story book will be written. Not fiction. Something like an iceberg drifting ever more southward into the warm Atlantic.
Wait a minute? Didn’t someone mention an Anavex iceberg sometime ago? What, per chance, might have prompted such an utterance? All of the above.
https://investorshub.advfn.com/boards/read_ms...=148898022
2
